215 related articles for article (PubMed ID: 20213332)
1. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Phuphanich S; Supko JG; Carson KA; Grossman SA; Burt Nabors L; Mikkelsen T; Lesser G; Rosenfeld S; Desideri S; Olson JJ
J Neurooncol; 2010 Oct; 100(1):95-103. PubMed ID: 20213332
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
[TBL] [Abstract][Full Text] [Related]
5. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
Horton TM; Pati D; Plon SE; Thompson PA; Bomgaars LR; Adamson PC; Ingle AM; Wright J; Brockman AH; Paton M; Blaney SM
Clin Cancer Res; 2007 Mar; 13(5):1516-22. PubMed ID: 17332297
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
12. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Raizer JJ; Chandler JP; Ferrarese R; Grimm SA; Levy RM; Muro K; Rosenow J; Helenowski I; Rademaker A; Paton M; Bredel M
J Neurooncol; 2016 Aug; 129(1):139-46. PubMed ID: 27300524
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Friday BB; Anderson SK; Buckner J; Yu C; Giannini C; Geoffroy F; Schwerkoske J; Mazurczak M; Gross H; Pajon E; Jaeckle K; Galanis E
Neuro Oncol; 2012 Feb; 14(2):215-21. PubMed ID: 22090453
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
19. A phase I study evaluating ibritumomab tiuxetan (ZevalinĀ®) in combination with bortezomib (VelcadeĀ®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]